The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised




About Embrella Cardiovascular

Embrella Cardiovascular is working on improving standards-of-care for cerebral embolic protection during cardiovascular procedures. The company believes that this technology can be successfully utilized as a safe, efficient, and cost effective method of preventing clot or debris from embolizing into the cerebral circulation during cardiovascular procedures.

Embrella Cardiovascular Headquarter Location

880 E. Swedesford Road Suite 220

Malvern, Pennsylvania, 19087,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Embrella Cardiovascular Patents

Embrella Cardiovascular has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Interventional radiology, Cardiac surgery, Vascular surgery, Stroke


Application Date


Grant Date



Related Topics

Vascular diseases, Interventional radiology, Cardiac surgery, Vascular surgery, Stroke



Latest Embrella Cardiovascular News

Biosig Brings Biostar Ventures Partner to Board

Dec 14, 2011

Biosig Brings Biostar Ventures Partner to Board December 14, 2011 By Angela Sormani Venture-backed BioSig Technologies, a medical device company developing clinical solutions for diagnoses and treatments of abnormal heart rhythms, has hired Jeffrey O’Donnell to the company’s board of directors. Currently, O’Donnell is a venture partner of Biostar Ventures, a venture capital firm investing in early stage medical device companies. Previously he was the CEO of Embrella Cardiovascular sold to Edwards Life Sciences earlier this year. PRESS RELEASE BioSig Technologies, Inc, a medical device company developing superior clinical solutions for diagnoses and treatments of abnormal heart rhythms, today announced that Jeffrey O’Donnell has joined the Company’s Board of Directors. Jeffrey O’Donnell commented, “I look forward to assisting the BioSig team develop a new standard of care with their game changing technology platform.” He continued, “I believe PURE will enhance EP ablation procedures by increasing outcomes for patients and decreasing cost to the healthcare system.” Mr. O’Donnell brings 28 years of experience in the healthcare industry in sales, marketing and management. Currently, Mr. O’Donnell is a Venture Partner of Biostar Ventures, a venture capital firm investing primarily in early stage medical device companies. Previously he was the CEO of Embrella Cardiovascular sold to Edwards Life Sciences earlier this year. Mr. O’Donnell has been the CEO of six medical device companies and held several senior management positions at Boston Scientific, Guidant Corporation and Johnson & Johnson. In 2011 Mr. O’Donnell was named Greater Philadelphia Emerging Entrepreneur of the Year by Ernst & Young and in 2005 he was named Life Science CEO of the year by Eastern Technology Council. Kenneth Londoner, CEO of BioSig, added, “We are delighted to have Jeffrey O’Donnell join our board. He brings a wealth of experience in the medical device arena and will be an invaluable asset on our board as we establish ourselves as an innovator in the electrophysiology community.” About BioSig Technologies: BioSig Technologies is a medical device company developing unique clinical solutions for diagnoses and treatments of abnormal heart rhythms (arrhythmias). BioSig’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) platform is designed to assist electrophysiologists during the termination of arrhythmias by cardiac ablation. PURE empowers electrophysiologists to make crucial clinical decisions in real time by providing information unobtainable with any other equipment presently in the electrophysiology (EP) lab. The Company is collaborating with physicians from the world-renowned Texas Cardiac Arrhythmia Institute (TCAI) in Austin, Texas. © 2015 Buyouts Insider / Argosy Group LLC

  • Where is Embrella Cardiovascular's headquarters?

    Embrella Cardiovascular's headquarters is located at 880 E. Swedesford Road, Malvern.

  • What is Embrella Cardiovascular's latest funding round?

    Embrella Cardiovascular's latest funding round is Acquired.

  • How much did Embrella Cardiovascular raise?

    Embrella Cardiovascular raised a total of $9M.

  • Who are the investors of Embrella Cardiovascular?

    Investors of Embrella Cardiovascular include Edwards Lifesciences, BioStar Capital, MedFocus Fund, Hatteras Venture Partners and Chartwell Investment Partners.

  • Who are Embrella Cardiovascular's competitors?

    Competitors of Embrella Cardiovascular include Cyberheart, Spectranetics, SciBase, Cameron Health, PEAK Surgical and 11 more.

You May Also Like


NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment.Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

Advanced Surgical Concepts

Advanced Surgical Concepts develops surgical instruments for use in endoscopy and in minimally invasive surgery


Developing minimally invasive methods and devices for treating congestive failure and cardiac valve diseasen(Acquired by ev3)


Endogun Medical Systems Ltd. is a medical device company developing: EndoFast Reliant„ system for Pelvic Organ Prolapse repair.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.